Metrikler
Yayın
218
Açık Erişim
38
BM Sürdürülebilir Kalkınma Amaçları
Eğitim Bilgileri
2007 - 2009
2007 - 2009Yüksek Lisans
Hacettepe Üniversitesi, Tıp Fakültesi-Kanser Enstitüsü, Kanser Epidemiyolojisi, Türkiye
2003 - 2009
2003 - 2009Tıpta Yandal Uzmanlık
Hacettepe Üniversitesi, İç Hastalıkları, Medikal Onkoloji, Türkiye
1998 - 2003
1998 - 2003Tıpta Uzmanlık
Hacettepe Üniversitesi, Tıp Fakültesi, İç Hastalıkları, Türkiye
1992 - 1998
1992 - 1998Lisans
Gazi Üniversitesi, Tıp Fakültesi, Türkiye
Araştırma Alanları
Tıp
Sağlık Bilimleri
Dahili Tıp Bilimleri
İç Hastalıkları
Onkoloji
Akademik Faaliyetlere Dayalı Araştırma Alanları
Avesis Araştırma Alanları
WoS Araştırma Alanları
Scopus Araştırma Alanları
Yönetimsel Görevler
2013 - Devam Ediyor
2013 - Devam EdiyorBölüm Başkan Yardımcısı
Hacettepe Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü
2010 - 2013
2010 - 2013Bölüm Başkanı
Cumhuriyet Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü
Yönetilen Tezler
2012
2012Tıpta Uzmanlık
Yeni evreleme sistemi mide kanserinde sağkalımı etkiliyor mu
KILIÇKAP S.
O.KIRBIYIK(Öğrenci)
Makaleler
Tümü (162)
SCI-E, SSCI, AHCI (149)
SCI-E, SSCI, AHCI, ESCI (157)
ESCI (7)
Scopus (157)
TRDizin (18)
2024
20241. Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial
Peters S., Gadgeel S. M., Mok T., Nadal E., KILIÇKAP S., Swalduz A., et al.
NATURE MEDICINE
, cilt.30, ss.1923-1932, 2024 (SCI-Expanded, Scopus)
2024
20242. Adrenocortical Cancer in the Real World: A Comprehensive Analysis of Clinical Features and Management from the Turkish Oncology Group (TOG)
YAŞAR H. A., AKTAŞ B. Y., Ucar G., SEZGİN GÖKSU S., Bilgetekin I., Cakar B., et al.
Clinical Genitourinary Cancer
, cilt.22, sa.3, 2024 (SCI-Expanded, Scopus)
2024
20243. A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy
KILIÇKAP S., Ozturk A., Karadurmus N., KORKMAZ T., YUMUK P. F., ÇİÇİN İ., et al.
MEDICINE
, cilt.103, sa.21, 2024 (SCI-Expanded, Scopus)
2024
20244. The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study
Yıldırım H. Ç., KUTLU Y., Mutlu E., Aykan M. B., Korkmaz M., Yalçın S., et al.
International Journal of Clinical Oncology
, cilt.29, sa.3, ss.258-265, 2024 (SCI-Expanded, Scopus)
2024
20245. A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)
Zhou C., Hu Y., Arkania E., Kilickap S., Ying K., Xu F., et al.
Cancer cell
, cilt.42, sa.2, ss.198-208, 2024 (SCI-Expanded, Scopus)
2024
20246. The efficacy of immunotherapy and chemoimmunotherapy in patients with advanced rare tumors: A Turkish oncology group (TOG) study
Guven D. C., Aykan M. B., MUĞLU H., BAYRAM E., Helvaci K., DURSUN B., et al.
Cancer Medicine
, cilt.13, sa.1, 2024 (SCI-Expanded, Scopus)
2024
20247. The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencing
KÖSTEK O., Demirel A., Hacıoğlu M. B., TAŞTEKİN D., KARABULUT S., Gündogdu A., et al.
Journal of Chemotherapy
, 2024 (SCI-Expanded, Scopus)
2024
20248. Genetic testing and counseling challenges in personalized breast cancer care: review article with insights from Türkiye
Cicin I., Karadurmus N., BİLİCİ A., Bahsi T., ŞENDUR M. A. N., Demirci U., et al.
FUTURE ONCOLOGY
, cilt.20, sa.15, ss.1031-1045, 2024 (SCI-Expanded, Scopus)
2023
20239. Mean Platelet Volume to Lymphocyte Ratio: A New Biomarker Predicting Response in Patients with Solid Tumors Treated with Nivolumab
YILDIRIM H. Ç., KUŞ F., GÜVEN D. C., Karaca E., KAYGUSUZ Y., DİZDAR Ö., et al.
Journal of Immunotherapy and Precision Oncology
, cilt.6, sa.4, ss.170-176, 2023 (Scopus)
2023
202310. The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors
GÜVEN D. C., ÖZBEK D. A., ŞAHİN T. K., KAVGACI G., Aksun M. S., ERUL E., et al.
Anti-Cancer Drugs
, cilt.34, sa.6, ss.783-790, 2023 (SCI-Expanded, Scopus)
2023
202311. The benefit of treatment beyond progression with immune checkpoint inhibitors: a multi-center retrospective cohort study
GÜVEN D. C., Yekeduz E., Erul E., YAZGAN S. C., ŞAHİN T. K., KARATAŞ G., et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
, cilt.149, sa.7, ss.3599-3606, 2023 (SCI-Expanded, Scopus)
2023
202312. Impact of pharmacist-led educational intervention on pneumococcal vaccination rates in cancer patients: a randomized controlled study
ÖZDEMİR N., AKTAŞ B. E., Gulmez A., İNKAYA A. Ç., Bayraktar-Ekincioglu A., Kilickap S., et al.
Supportive Care in Cancer
, cilt.31, sa.3, 2023 (SCI-Expanded, Scopus)
2023
202313. Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy
GÜVEN D. C., Incesu F. G. G., YILDIRIM H. Ç., Erul E., Chalabiyev E., AKTAŞ B. Y., et al.
INTERNATIONAL JOURNAL OF CANCER
, cilt.152, ss.679-685, 2023 (SCI-Expanded, Scopus)
2023
202314. External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database
Yekedüz E., Karakaya S., Ertürk İ., Tural D., Uçar G., Şentürk Öztaş N., et al.
Clinical Genitourinary Cancer
, cilt.21, sa.1, ss.175-182, 2023 (SCI-Expanded, Scopus)
2023
202315. Intracerebral de novo arterio-venous malformations as a side effect of bevacizumab
Elmali A., GÖÇMEN R., KILIÇKAP S., YAZICI G.
Journal of Oncology Pharmacy Practice
, 2023 (SCI-Expanded, Scopus)
2022
202216. Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study
YILDIRIM H. Ç., MUTLU E., Chalabiyev E., Ozen M., KESKİNKILIÇ M., ÖN S., et al.
BREAST
, cilt.66, ss.85-88, 2022 (SCI-Expanded, Scopus)
2022
202217. The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study
Yekeduz E., Tural D., Erturk I., Karakaya S., EROL C., Ercelep O., et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
, cilt.148, sa.12, ss.3537-3546, 2022 (SCI-Expanded, Scopus)
2022
202218. The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitors
Yucel K. B., Yekeduz E., Karakaya S., Tural D., Erturk I., EROL C., et al.
SCIENTIFIC REPORTS
, cilt.12, sa.1, 2022 (SCI-Expanded, Scopus)
2022
202219. Oncologists' attitudes towards prophylaxis of cancer associated venous thromboembolism: A prospective, descriptive study
Kandemir E. A., EKİNCİOĞLU A., KILIÇKAP S.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
, cilt.28, sa.7, ss.1560-1567, 2022 (SCI-Expanded, Scopus)
2022
202220. The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy
GÜVEN D. C., ŞAHİN T. K., Erul E., ÇAKIR İ. Y., ÜÇGÜL E., YILDIRIM H. Ç., et al.
JOURNAL OF CLINICAL MEDICINE
, cilt.11, sa.15, 2022 (SCI-Expanded, Scopus)
2022
202221. Severe progressive dermatomyositis in a patient with metastatic ovarian cancer using bevacizumab
MENTEŞOĞLU D., DOĞAN GÜNAYDIN S., ERSOY EVANS S., Atakan N., GÖKÖZ Ö., KARADAĞ Ö., et al.
INDIAN JOURNAL OF PHARMACOLOGY
, cilt.54, sa.4, ss.295-296, 2022 (SCI-Expanded, Scopus)
2022
202222. Trastuzumab +/- Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group
Gurbuz M., Akkus E., Sakin A., Urvay S., Demiray A. G., Sahin S., et al.
JOURNAL OF GASTROINTESTINAL CANCER
, cilt.53, sa.2, ss.282-288, 2022 (ESCI, Scopus)
2022
202223. The Association between the Pan-Immune-Inflammation Value and Cancer Prognosis: A Systematic Review and Meta-Analysis
GÜVEN D. C., ŞAHİN T. K., Erul E., KILIÇKAP S., Gambichler T., AKSOY S.
CANCERS
, cilt.14, sa.11, 2022 (SCI-Expanded, Scopus)
2022
202224. The burden of polypharmacy and drug-drug interactions in older cancer patients treated with immunotherapy
GÜVEN D. C., KAVGACI G., AKTEPE O. H., YILDIRIM H. H., ŞAHİN T. K., AKSOY S., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
, cilt.28, sa.4, ss.785-793, 2022 (SCI-Expanded, Scopus)
2022
202225. Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: A multicenter study
Yekeduz E., Ozbay M. F., Caglayan D., Yildirim A., Erol C., Yildirim H. C., et al.
JOURNAL OF CLINICAL ONCOLOGY
, cilt.40, sa.4, 2022 (SCI-Expanded, Scopus)
2022
202226. Long-term outcome and safety in patients treated with immune checkpoint blockade therapies for urothelial carcinoma: Experience from real-world clinical practice.
Tural D., Arslan C., Selcukbiricik F., Olmez O. F., Erman M., Urun Y., et al.
JOURNAL OF CLINICAL ONCOLOGY
, cilt.40, sa.6, 2022 (SCI-Expanded, Scopus)
2022
202227. First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer
Esen S. A., Ergun Y., Erol C., Arikan R., Er M. M., Atci M. M., et al.
Bosnian Journal of Basic Medical Sciences
, cilt.22, sa.5, ss.818-825, 2022 (SCI-Expanded, Scopus)
2022
202228. Pazopanib-induced chylothorax in a patient with renal cell carcinoma
KÖYLÜ B., TEKİN F., AKTAŞ B. Y., KILIÇKAP S., KÖKSAL D.
ANTI-CANCER DRUGS
, cilt.33, sa.1, 2022 (SCI-Expanded, Scopus)
2021
202129. Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database
Yekeduz E., Erturk I., Tural D., Karadurmus N., Karakaya S., Hizal M., et al.
FUTURE ONCOLOGY
, cilt.17, ss.4861-4869, 2021 (SCI-Expanded, Scopus)
2021
202130. The association between antibiotic use and survival in renal cell carcinoma patients treated with immunotherapy: a multi-center study
GÜVEN D. C., Acar R., Yekeduz E., Bilgetekin I., Baytemur N. K., EROL C., et al.
CURRENT PROBLEMS IN CANCER
, cilt.45, sa.6, 2021 (SCI-Expanded, Scopus)
2021
202131. Thirty-day mortality rates after immunotherapy initiation
SÜTCÜOĞLU O., Ilhan A., Tacar S. Y., GÜVEN D. C., Ucar G., Karadurmus N., et al.
IMMUNOTHERAPY
, cilt.13, ss.1419-1426, 2021 (SCI-Expanded, Scopus)
2021
202132. The association of BMI and sarcopenia with survival in patients with glioblastoma multiforme
GÜVEN D. C., AKSUN M. S., ÇAKIR İ. Y., KILIÇKAP S., KERTMEN N.
FUTURE ONCOLOGY
, cilt.17, ss.4405-4413, 2021 (SCI-Expanded, Scopus)
2021
202133. Antibody Responses to COVID-19 Vaccination in Cancer: A Systematic Review
GÜVEN D. C., ŞAHİN T. K., KILIÇKAP S., Uckun F. M.
FRONTIERS IN ONCOLOGY
, cilt.11, 2021 (SCI-Expanded, Scopus)
2021
202134. Newly diagnosed cancer and the COVID-19 pandemic: tumour stage migration and higher early mortality
GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., ÇEŞMECİ E., Incesu F. G. G., TAHILLIOĞLU Y., et al.
BMJ SUPPORTIVE & PALLIATIVE CARE
, 2021 (SCI-Expanded, Scopus)
2021
202135. Initiation of Chemosaturation With Percutaneous Hepatic Perfusion Program in Interventional Radiology Department
ÖCAL O., Eldem G., KARAGÖZ A. H., KILIÇKAP S., YALÇIN Ş., BALKANCI F., et al.
CUREUS
, cilt.13, sa.9, 2021 (ESCI)
2021
202136. Lower prognostic nutritional index is associated with poorer survival in patients receiving immune-checkpoint inhibitors
GÜVEN D. C., AKTEPE O. H., TABAN H., AKTAŞ B. Y., GÜNER G., YILDIRIM H. H., et al.
BIOMARKERS IN MEDICINE
, cilt.15, sa.13, ss.1123-1130, 2021 (SCI-Expanded, Scopus)
2021
202137. Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy
GÜVEN D. C., AKSUN M. S., ŞAHİN T. K., AKTEPE O. H., YILDIRIM H. Ç., TABAN H., et al.
SUPPORTIVE CARE IN CANCER
, cilt.29, sa.9, ss.5417-5423, 2021 (SCI-Expanded, Scopus)
2021
202138. Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience
Bahceci A., PAYDAŞ S., Ak N., Ferhatoglu F., Saip P. M., SEYDAOĞLU G., et al.
CANCER INVESTIGATION
, cilt.39, sa.6-7, ss.473-481, 2021 (SCI-Expanded, Scopus)
2021
202139. Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab
Tural D., Olmez O. F., Sumbul A. T., Ozhan N., ÇAKAR B., Kostek O., et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
, cilt.26, ss.1506-1513, 2021 (SCI-Expanded, Scopus)
2021
202140. Comparison of respiratory muscle strength and endurance, maximal oxygen consumption, and fatigue in colorectal cancer survivors with healthy adults
Sanver M. F., VARDAR YAĞLI N., SAĞLAM M., TEKERLEK H., ÇALIK KÜTÜKCÜ E., İNAL İNCE D., et al.
SUPPORTIVE CARE IN CANCER
, cilt.29, sa.7, ss.3903-3909, 2021 (SCI-Expanded, Scopus)
2021
202141. Chemoimmunotherapy for the salvage treatment of Ewing sarcoma: A case report
GÜVEN D. C., KILIÇKAP S., YILDIRIM H. Ç., Ceylan F., BAŞ O., DİZDAR Ö.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
, cilt.27, sa.5, ss.1281-1283, 2021 (SCI-Expanded, Scopus)
2021
202142. The effect of the COVID-19 pandemic on routine adult vaccination in cancer patients
ÖZDEMİR N., Bayraktar-Ekincioglu A., KILIÇKAP S.
MEDICAL ONCOLOGY
, cilt.38, sa.6, 2021 (SCI-Expanded, Scopus)
2021
202143. Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%: EMPOWER-Lung 1 subgroup analysis.
Ozguroglu M., Sezer A., Kilickap S., Gumus M., Bondarenko I., Gogishvili M., et al.
JOURNAL OF CLINICAL ONCOLOGY
, cilt.39, sa.15, 2021 (SCI-Expanded, Scopus)
2021
202144. Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 >= 50%: Results from EMPOWER-Lung 1 study.
Gumus M., Chen C., Ivanescu C., Kilickap S., Bondarenko I., Ozguroglu M., et al.
JOURNAL OF CLINICAL ONCOLOGY
, cilt.39, sa.15, 2021 (SCI-Expanded, Scopus)
2021
202145. THE INCIDENCE AND RISK FACTORS FOR ACUTE KIDNEY INJURY IN PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: A REAL-LIFE STUDY
GÜVEN D. C., ÖZBEK D. A., ŞAHİN T. K., AKSUN M. S., KAVGACI G., Cebrayilov C., et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION
, cilt.36, 2021 (SCI-Expanded, Scopus)
2021
202146. Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors
GÜVEN D. C., ŞAHİN T. K., AKSUN M. S., TABAN H., AKTEPE O. H., METİN AKSU N., et al.
SUPPORTIVE CARE IN CANCER
, cilt.29, sa.4, ss.2029-2035, 2021 (SCI-Expanded, Scopus)
2021
202147. Assessment of adherence to cancer-associated venous thromboembolism guideline and pharmacist's impact on anticoagulant therapy
Kandemir E. A., EKİNCİOĞLU A., KILIÇKAP S.
SUPPORTIVE CARE IN CANCER
, cilt.29, sa.3, ss.1699-1709, 2021 (SCI-Expanded, Scopus)
2021
202148. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
Sezer A., KILIÇKAP S., GÜMÜŞ M., Bondarenko I., ÖZGÜROĞLU M., Gogishvili M., et al.
LANCET
, cilt.397, sa.10274, ss.592-604, 2021 (SCI-Expanded, Scopus)
2021
202149. Nivolumab as second-line treatment and beyond for metastatic renal cell carcinoma: A real-life experience from Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database.
Yekeduz E., Erturk I., Tural D., Karadurmus N., Karakaya S., Hizal M., et al.
JOURNAL OF CLINICAL ONCOLOGY
, cilt.39, sa.6, 2021 (SCI-Expanded, Scopus)
2021
202150. Factors affecting the response to Y-90 microsphere therapy in the cholangiocarcinoma patients
Bozkurt M., Eldem G., Bozbulut U. B., BOZKURT M. F., KILIÇKAP S., PEYNİRCİOĞLU B., et al.
RADIOLOGIA MEDICA
, cilt.126, sa.2, ss.323-333, 2021 (SCI-Expanded, Scopus)
2021
202151. Factors Affecting Survival in Retroperitoneal Sarcomas Treated with Upfront Surgery: A Real-World Study by Turkish Oncology Group
Akagunduz B., AKIN TELLİ T., YILDIRIM H. Ç., SEZGİN GÖKSU S., DEMİR N., Hafizoglu E., et al.
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
, cilt.31, sa.2, ss.92-98, 2021 (SCI-Expanded, Scopus, TRDizin)
2020
202052. GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients
Peled N., Gillis R., KILIÇKAP S., Froesch P., Orlov S., Filippova E., et al.
LUNG CANCER
, cilt.148, ss.48-54, 2020 (SCI-Expanded, Scopus)
2020
202053. Predictive biomarkers for immunotherapy efficacy in non-small-cell lung cancer: current status and future perspectives
C Guven D., ŞAHİN T. K., DİZDAR Ö., KILIÇKAP S.
BIOMARKERS IN MEDICINE
, cilt.14, ss.1383-1392, 2020 (SCI-Expanded, Scopus)
2020
202054. Neutrophil-lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study)
HIZAL M., ŞENDUR M. A. N., YAŞAR H. A., Bir Yucel K., Arslan C., Ucar G., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
, cilt.26, sa.7, ss.1583-1589, 2020 (SCI-Expanded, Scopus)
2020
202055. Survey of the Impact of COVID-19 on Oncologists' Decision Making in Cancer
Uruen Y., Hussain S. A., Bakouny Z., Castellano D., KILIÇKAP S., Morgan G., et al.
JCO GLOBAL ONCOLOGY
, cilt.6, ss.1248-1257, 2020 (ESCI, Scopus)
2020
202056. Perspectives, Knowledge, and Fears of Cancer Patients About COVID-19
GÜVEN D. C., ŞAHİN T. K., AKTEPE O. H., YILDIRIM H. Ç., AKSOY S., KILIÇKAP S.
FRONTIERS IN ONCOLOGY
, cilt.10, 2020 (SCI-Expanded, Scopus)
2020
202057. Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey
Hacioglu M. B., Kostek O., Karabulut S., Tastekin D., SEZGİN GÖKSU S., Alandag C., et al.
JOURNAL OF BUON
, cilt.25, sa.4, ss.1897-1903, 2020 (SCI-Expanded, Scopus)
2020
202058. The Impact of Everolimus and Radiation Therapy on Pulmonary Fibrosis
Eren M. F., Eren A. A., Sayan M., YÜCEL B., Elagoz S., Ozguven Y., et al.
MEDICINA-LITHUANIA
, cilt.56, sa.7, 2020 (SCI-Expanded, Scopus)
2020
202059. The relationship between prognostic nutritional index and treatment response in patients with metastatic renal cell cancer
YAŞAR H. A., Yucel K. B., Arslan C., Ucar G., Karakaya S., Bilgin B., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
, cilt.26, sa.5, ss.1110-1116, 2020 (SCI-Expanded, Scopus)
2020
202060. Drug-related problems with targeted/immunotherapies at an oncology outpatient clinic
Kucuk E., EKİNCİOĞLU A., ERMAN M., KILIÇKAP S.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
, cilt.26, sa.3, ss.595-602, 2020 (SCI-Expanded, Scopus)
2020
202061. Complete responses to two different anti-PD1 agents in a metastatic melanoma patient
KILIÇKAP S., GÜVEN D. C., AKTEPE O. H., AKTAŞ B. Y., DİZDAR Ö.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
, cilt.26, sa.2, ss.496-499, 2020 (SCI-Expanded, Scopus)
2020
202062. Prognostic factors for survival in patients with mucosal and ocular melanoma treated with ipilimumab: Turkish Oncology Group study
Yasar H. A., Turna H., Esin E., Sedef A. M., Alkan A., Oksuzoglu B., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
, cilt.26, sa.2, ss.267-272, 2020 (SCI-Expanded, Scopus)
2020
202063. Prognostic value of the 2017 World Health Organization Classification System for gastric neuroendocrine tumors: A single-center experience
Karakas Y., Lacin S., KURTULAN O., Esin E., Sunar V., SÖKMENSÜER C., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY
, cilt.31, sa.2, ss.91-98, 2020 (SCI-Expanded, Scopus, TRDizin)
2020
202064. Development of de novo psoriasis during nivolumab therapy in a patient with small cell lung cancer
GÜVEN D. C., KILIÇKAP S., GÜNER G., TABAN H., DİZDAR Ö.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
, cilt.26, sa.1, ss.256-258, 2020 (SCI-Expanded, Scopus)
2020
202065. The Effects of Different Treatment Modalities on the Disease Course and Survival in Patients with Hepatocellular Cancer
Lacin S., Karakas Y., DİZDAR Ö., KILIÇKAP S., Hassan M. M., Xiao L., et al.
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
, cilt.30, sa.2, ss.94-102, 2020 (SCI-Expanded, Scopus, TRDizin)
2019
201966. Re: Combination of radiotherapy and immunotherapy? Do timing and dose matter?
ÜRÜN Y., Yasar H. A., TURNA Z. H., KILIÇKAP S., Sezer A., Oksuzoglu B., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
, cilt.25, sa.8, ss.2062-2063, 2019 (SCI-Expanded, Scopus)
2019
201967. Prognostic factors for survival in patients with metastatic malign melanoma treated with ipilimumab: Turkish Oncology Group study
ÜRÜN Y., Yasar H. A., TURNA Z. H., Esin E., Sedef A. M., Alkan A., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
, cilt.25, sa.7, ss.1658-1664, 2019 (SCI-Expanded, Scopus)
2019
201968. Adaptation of Error Adjusted Bagging Method for Prediction
Isikhan S., KARABULUT E., Samadi A., KILIÇKAP S.
INTERNATIONAL JOURNAL OF DATA WAREHOUSING AND MINING
, cilt.15, sa.3, ss.28-45, 2019 (SCI-Expanded, Scopus)
2019
201969. Outcomes of Radioembolization in Patients with Chemorefractory Colorectal Cancer Liver Metastasis: a Single-Center Experience
TÜRK G., Eldem G., KILIÇKAP S., Bozkurt F. M., VOLKAN SALANCI B., ÇİL B. E., et al.
JOURNAL OF GASTROINTESTINAL CANCER
, cilt.50, sa.2, ss.236-243, 2019 (ESCI, Scopus)
2019
201970. Analysis of Fusobacterium nucleatum and Streptococcus gallolyticus in saliva of colorectal cancer patients
Guven D. C., DİZDAR Ö., ALP A., AKDOĞAN KITTANA F. N., KARAKOÇ D., HAMALOĞLU E., et al.
BIOMARKERS IN MEDICINE
, cilt.13, sa.9, ss.725-735, 2019 (SCI-Expanded, Scopus)
2019
201971. Short-time use of crizotinib as neoadjuvant in ALK-positive non-small cell lung carcinoma can be a chance for resectability
KILIÇKAP S., Onder S., DİZDAR Ö., ERMAN M., ÜNER A.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
, cilt.83, sa.6, ss.1195-1196, 2019 (SCI-Expanded, Scopus)
2019
201972. Reproductive cancer risk factors among relatives of cancer patients in a tertiary oncology center
Atta N., KILIÇKAP S., YÜCE D., Hayran M.
BMC CANCER
, cilt.19, 2019 (SCI-Expanded, Scopus)
2019
201973. Critical Role of Ga-68 DOTATATE PET-CT in a Patient with Neuroendocrine Tumor and Second Primary Cancer
TELLİ T., TUNCEL M., KILIÇKAP S.
TURKISH JOURNAL OF ENDOCRINOLOGY AND METABOLISM
, cilt.23, sa.1, ss.58-63, 2019 (ESCI, Scopus, TRDizin)
2019
201974. Sicca/Sjogren's syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR)
Ramos-Casals M., Maria A., Suarez-Almazor M. E., Lambotte O., Fisher B. A., Hernandez-Molina G., et al.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
, cilt.37, sa.3, 2019 (SCI-Expanded, Scopus)
2018
201875. EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS IN TREATMENT OF NON-SMALL CELL LUNG CANCER
KILIÇKAP S.
NOBEL MEDICUS
, cilt.14, sa.3, ss.5-8, 2018 (ESCI, Scopus)
2018
201876. Factors associated with quitting action following smoking cessation counseling.
Hayran K. M., Yuce D., Erman M., Dizdar O., Kilickap S., HUSEYIN B.
JOURNAL OF CLINICAL ONCOLOGY
, cilt.36, sa.15, 2018 (SCI-Expanded, Scopus)
2018
201877. Starting of biological disease modifying antirheumatic drugs may be postponed in rheumatoid arthritis patients with multimorbidity: Single center real life results
ARMAĞAN B., SARI A., ERDEN A., KILIÇ L., ERDAT E. C., KILIÇKAP S., et al.
MEDICINE
, cilt.97, sa.13, 2018 (SCI-Expanded, Scopus)
2018
201878. Changes in lifestyle upon diagnosis of cancer or other chronic illnesses: A Turkish Oncology Group study
Turhal N. S., Akinci F., Haciabdullahoglu Y., Dolmaci M., Sari A., GÜRHAN N., et al.
JOURNAL OF HEALTH PSYCHOLOGY
, cilt.23, sa.4, ss.561-566, 2018 (SSCI, Scopus)
2018
201879. Evaluation of G-CSF (granulocyte colony stimulating factor) use in oncology outpatient clinic by the PRS (patient risk score) assessment
ARAS E., Tecen K., Bayraktar-Ekincioglu A., Demirkan K., KILIÇKAP S.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY
, cilt.40, sa.1, ss.247, 2018 (SCI-Expanded, Scopus)
2018
201880. Clinical Pharmacy Practices in Oncology Patients Treated with Tyrosine Kinase Inhibitors
Tecen-Yucel K., Bayraktar-Ekincioglu A., KILIÇKAP S., ERMAN M.
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
, cilt.28, sa.1, ss.53-60, 2018 (SCI-Expanded, Scopus, TRDizin)
2018
201881. Epidemiyoloji ve Etiyoloji
YÜCE D., KILIÇKAP S.
Türkiye Klinikleri Tip Bilimleri Dergisi , 2018 (Scopus, TRDizin)
2018
201882. Endpoints in oncology clinical trials
KILIÇKAP S., Demirci U., Karadurmus N., Dogan M., Akinci B., ŞENDUR M. A. N.
JOURNAL OF BUON
, cilt.23, 2018 (SCI-Expanded, Scopus)
2017
201783. BİR SİGARA BIRAKMA POLİKLİNİĞİNDE UYGULANAN PSİKOEĞİTİMSEL SİGARA BIRAKMA POROGRAMININ ETKİNLİĞİ
KAMIŞLI S., YÜCE D., küçükçoban ş., HAYRAN K. M., KILIÇKAP S., ÇELİK İ., et al.
Anadolu Hemşirelik ve Sağlık Bilimleri Dergisi , cilt.20, sa.4, ss.234-242, 2017 (TRDizin)
2017
201784. Immune Thrombocytopenia Induced by Nivolumab in a Metastatic Non-Small Cell Lung Cancer Patient
Karakas Y., YÜCE D., KILIÇKAP S.
ONCOLOGY RESEARCH AND TREATMENT
, cilt.40, sa.10, ss.621-622, 2017 (SCI-Expanded, Scopus)
2017
201785. Reinforcement of mental health in an interaction group of cancer patients
HAYRAN K. M., Kamisli S., Kucukcoban S., ÇELİK İ., KILIÇKAP S., YÜCE D.
PSYCHO-ONCOLOGY
, cilt.26, ss.161, 2017 (SCI-Expanded, SSCI, Scopus)
2017
201786. Cancer patients and oncology nursing from the perspectives of oncology nurses in Turkey
Kamisli S., YÜCE D., Karakilic B., KILIÇKAP S., HAYRAN K. M.
PSYCHO-ONCOLOGY
, cilt.26, ss.145, 2017 (SCI-Expanded, SSCI, Scopus)
2017
201787. Is plasma caveolin-1 level a prognostic biomarker in metastatic pancreatic cancer?
Demirci N. S., Dogan M., Erdem G. U., Kacar S., Turhan T., KILIÇKAP S., et al.
SAUDI JOURNAL OF GASTROENTEROLOGY
, cilt.23, sa.3, ss.183-189, 2017 (SCI-Expanded, Scopus)
2017
201788. Evaluation of complementary and alternative medicine trials registered in clinicaltrials.gov database
DİZDAR Ö., BİLGİN E., AKIN S., KILIÇKAP S., HAYRAN M.
JOURNAL OF BUON
, cilt.22, sa.2, ss.530-534, 2017 (SCI-Expanded, Scopus)
2017
201789. Retention Rate of Etanercept in Patients with Rheumatoid Arthritis Is Better Than That of Monoclonal Antibody
ERDEN A., KILIÇ L., KARADAĞ Ö., KİRAZ S., KILIÇKAP S., AKDOĞAN A., et al.
Acta Medica , cilt.48, sa.3, ss.11-17, 2017 (TRDizin)
2017
201790. A giant polypoid mass leading to obstruction in the colon
KÖKLÜ H., ÖZTÜRK Ö., Koklu S., Saglam A., KARÇAALTINCABA M., KILIÇKAP S.
ACTA GASTRO-ENTEROLOGICA BELGICA
, cilt.80, sa.1, ss.93-94, 2017 (SCI-Expanded, Scopus)
2017
201791. Attitudes of cancer patients after diagnosis: How cancer affects social life? A Turkish Oncology Group study
Nayir E., Koyuncu M. B., Esin E., Turker I., TANRIVERDİ Ö., UYSAL M., et al.
JOURNAL OF BUON
, cilt.22, sa.1, ss.208-213, 2017 (SCI-Expanded, Scopus)
2017
201792. A critical analysis of publication rates of national oncology meeting abstracts in Turkey
KILIÇKAP S., Hüseyin B., Esin E., YÜCE D., HAYRAN K. M.
Journal of Oncological Sciences , ss.1-5, 2017 (TRDizin)
2017
201793. Evaluation of risk factors for the recurrence of colorectal polyps and colorectal cancer
ATEŞ Ö., SİVRİ B., KILIÇKAP S.
TURKISH JOURNAL OF MEDICAL SCIENCES
, cilt.47, sa.5, ss.1370-1376, 2017 (SCI-Expanded, Scopus, TRDizin)
2016
201694. Does Adjuvant Hormone Therapy Improve Survival in Epithelial Ovarian Cancer?
KILIÇKAP S., Tural D.
JOURNAL OF CLINICAL ONCOLOGY
, cilt.34, sa.17, ss.2069-2070, 2016 (SCI-Expanded, Scopus)
2016
201695. Tendency of cancer patients and their relatives to use Internet for health-related searches: Turkish Oncology Group (TOG) Study
Nayir E., TANRIVERDİ Ö., Karakas Y., KILIÇKAP S., Turhal N. S., Avci N., et al.
JOURNAL OF BUON
, cilt.21, sa.3, ss.714-719, 2016 (SCI-Expanded, Scopus)
2016
201696. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer
ATEŞ Ö., BABACAN T., KERTMEN N., Sarici F., Cenoli A., AKIN S., et al.
JOURNAL OF BUON
, cilt.21, sa.2, ss.375-381, 2016 (SCI-Expanded, Scopus)
2016
201697. Anthracyclin - Based Chemotherapy in Patients with Non-Hodgkin Lymphoma Aged Over 75
Sarici F., KERTMEN N., Aslan A. C., Tasdemir V., BABACAN T., KILIÇKAP S., et al.
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
, cilt.26, sa.2, ss.89-95, 2016 (SCI-Expanded, Scopus, TRDizin)
2016
201698. The prognostic value of UHRF-1 and p53 in gastric cancer
AKGÜL BABACAN N., EĞİLMEZ H. R., YÜCEL B., Parlak I., ŞEKER M. M., KAÇAN T., et al.
SAUDI JOURNAL OF GASTROENTEROLOGY
, cilt.22, sa.1, ss.25-29, 2016 (SCI-Expanded, Scopus)
2016
201699. The Relationship of Agmatine Deficiency with the Lung Cancer
KAPANCIK S., ÇELİK V. K., KILIÇKAP S., Kacan T., Kapancik S.
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
, cilt.26, sa.2, ss.103-109, 2016 (SCI-Expanded, Scopus, TRDizin)
2016
2016100. Akciğer Kanserinde Erken Tanı ve Tarama Programlarındaki Gelişmeler
YÜCE D., KILIÇKAP S.
Turkiye Klinikleri Journal of Medical Oncology Special Topics
, cilt.9, sa.4, ss.1-5, 2016 (TRDizin)
2016
2016101. The Prognostic Value of High Pretreatment Plasma D-Dimer Levels in Non-Metastatic Breast Cancer Patients with Absence of Venous Thromboembolism
Kacan T., YÜCEL B., BAHAR S., Celasun G., Seker M. M., Babacan N., et al.
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
, cilt.26, sa.3, ss.136-144, 2016 (SCI-Expanded, Scopus, TRDizin)
2016
2016102. Effect of Zoledronic Acid on Rats' Tissue SDF-1 Expression
Arik Z., KILIÇKAP S., AKPULAT U., Nahit Sendur M. A., KOCAEFE Y. Ç., ERMAN M.
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
, cilt.26, sa.4, ss.215-219, 2016 (SCI-Expanded, Scopus, TRDizin)
2015
2015103. Significant Association Between Polymorphisms of Wnt Antagonist Genes and Lung Cancer
YILMAZ M., DÖNMEZ G., KAÇAN T., SARI İ., Babacan N. A., SARİ M., et al.
JOURNAL OF INVESTIGATIVE MEDICINE
, cilt.63, sa.8, ss.935-941, 2015 (SCI-Expanded, Scopus)
2015
2015104. Cutaneous melanoma in Turkey: analysis of 1157 patients in the Melanoma Turkish Study
Abali H., ÇELİK İ., Karaca B., TURNA Z. H., Saglam E. K., Akman T., et al.
JOURNAL OF BUON
, cilt.20, sa.4, ss.1137-1141, 2015 (SCI-Expanded, Scopus)
2015
2015105. QUALITY OF LIFE DOMAINS ASSOCIATED WITH READMISSION
HAYRAN K. M., YÜCE D., Huseyin B., Esin E., KILIÇKAP S., ERMAN M., et al.
VALUE IN HEALTH
, cilt.18, sa.3, 2015 (SCI-Expanded, SSCI, Scopus)
2015
2015106. Improved Anti-Emetic Efficacy of 5-HT3 Receptor Antagonists in Cancer Patients with Genetic Polymorphisms of ABCB1 (MDR1) Drug Transporter
Zoto T., KILIÇKAP S., YAŞAR Ü., ÇELİK İ., BOZKURT A., BABAOĞLU M. Ö.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
, cilt.116, sa.4, ss.354-360, 2015 (SCI-Expanded, Scopus)
2015
2015107. A Case of Multifocal Skin Metastases from Lung Cancer Presenting with Vasculitic-type Cutaneous Nodule
AKGÜL BABACAN N., KILIÇKAP S., Sene S., KAÇAN T., YÜCEL B., EREN M. F., et al.
INDIAN JOURNAL OF DERMATOLOGY
, cilt.60, sa.2, 2015 (SCI-Expanded, Scopus)
2015
2015108. Mortality in Colorectal Cancer and Use of Statins
Tural D., KILIÇKAP S.
JOURNAL OF CLINICAL ONCOLOGY
, cilt.33, sa.7, ss.810, 2015 (SCI-Expanded, Scopus)
2015
2015109. First-Line Crizotinib in ALK-Positive Lung Cancer
Tural D., KILIÇKAP S.
NEW ENGLAND JOURNAL OF MEDICINE
, cilt.372, sa.8, ss.781, 2015 (SCI-Expanded, Scopus)
2015
2015110. Nationwide Smoking Cessation Treatment Support Program - Turkey project
ÇELİK İ., YÜCE D., Hayran M., ERMAN M., KILIÇKAP S., BUZĞAN T., et al.
HEALTH POLICY
, cilt.119, sa.1, ss.50-56, 2015 (SCI-Expanded, SSCI, Scopus)
2015
2015111. Generic Imatinib Mesylate is as Effective as Original Glivec in the Clinical Management of CML
Malkan U. Y., AKSU S., Aktimur S. H., Atay H., Bektas O., BÜYÜKAŞIK Y., et al.
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
, cilt.25, sa.4, ss.215-221, 2015 (SCI-Expanded, Scopus, TRDizin)
2014
2014112. HEALTH RELATED QUALITY OF LIFE IN CANCER PATIENTS: EVALUATION WITH A SELF-ADMINISTERED IPAD APPLICATION
YÜCE D., HAYRAN K. M., KILIÇKAP S., ERMAN M., ÇELİK İ.
VALUE IN HEALTH
, cilt.17, sa.7, 2014 (SCI-Expanded, SSCI, Scopus)
2014
2014113. ASSOCIATION OF HEALTH CARE COST WITH QUALITY OF LIFE FOR VARIOUS TYPES OF CANCERS
HAYRAN K. M., YÜCE D., Huseyin B., Esin E., KILIÇKAP S., ERMAN M., et al.
VALUE IN HEALTH
, cilt.17, sa.7, 2014 (SCI-Expanded, SSCI, Scopus)
2014
2014114. Bone Metastasis from Gastric Cancer: The Incidence, Clinicopathological Features, and Influence on Survival
Turkoz F. P., Solak M., KILIÇKAP S., Ulas A., Esbah O., Oksuzoglu B., et al.
JOURNAL OF GASTRIC CANCER
, cilt.14, sa.3, ss.164-172, 2014 (ESCI, Scopus)
2014
2014115. Study of interaction with a group of cancer patients: guiding cancer patients through psychoeducational interventions
Kamisli S., HAYRAN K. M., Kucukcoban S., KILIÇKAP S., YÜCE D., ÇELİK İ.
EUROPEAN JOURNAL OF ONCOLOGY NURSING
, cilt.18, 2014 (SCI-Expanded, SSCI, Scopus)
2014
2014116. P95 HER2 fragments and breast cancer outcome
Tural D., Akar E., Mutlu H., KILIÇKAP S.
EXPERT REVIEW OF ANTICANCER THERAPY
, cilt.14, sa.9, ss.1089-1096, 2014 (SCI-Expanded, Scopus)
2014
2014117. Mortality in Prostate Cancer and Use of Statins
Tural D., YÜCE D., KILIÇKAP S.
JOURNAL OF CLINICAL ONCOLOGY
, cilt.32, sa.21, ss.2274, 2014 (SCI-Expanded, Scopus)
2014
2014118. End-of-study results of Turkish gastric cancer patients from the global REGATE study
YALÇIN Ş., Gumus M., KILIÇKAP S., Alkis N., Ilhan M., Oksuzoglu B., et al.
JOURNAL OF BUON
, cilt.19, sa.2, ss.377-387, 2014 (SCI-Expanded, Scopus)
2014
2014119. Lung Cancer in Women: A Single Institution Experience with 50 Patients
AKGÜL BABACAN N., YÜCEL B., KILIÇKAP S., ŞEKER M. M., KAÇAN T., KOÇ OLÇAŞ İ., et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION
, cilt.15, sa.1, ss.151-154, 2014 (SCI-Expanded, Scopus)
2014
2014120. Lack of Association between the MTHFR C677T Polymorphism and Lung Cancer in a Turkish Population
YILMAZ M., KAÇAN T., SARI İ., KILIÇKAP S.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION
, cilt.15, sa.15, ss.6333-6337, 2014 (SCI-Expanded, Scopus)
2014
2014121. Higher Ki67 Expression is Associates With Unfavorable Prognostic Factors and Shorter Survival in Breast Cancer
KILIÇKAP S., KAYA Y., YÜCEL B., TUNCER E., AKGÜL BABACAN N., Elagoz S.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION
, cilt.15, sa.3, ss.1381-1385, 2014 (SCI-Expanded, Scopus)
2013
2013122. Therapeutic Proteins in Tumors and Targeted Therapeutic Agents for Cancer Patients
KESİKLİ S. A., KILIÇKAP S.
PROTEIN AND PEPTIDE LETTERS
, cilt.20, sa.12, ss.1345-1359, 2013 (SCI-Expanded, Scopus)
2013
2013123. Dose-dense effect: other contributors
KESİKLİ S. A., YÜCE D., KILIÇKAP S.
LANCET ONCOLOGY
, cilt.14, sa.12, 2013 (SCI-Expanded, Scopus)
2013
2013124. Aromatase Inhibitors and Safety: Clinical or Statistical Significance?
Esin E., YÜCE D., KILIÇKAP S., ERMAN M.
JOURNAL OF CLINICAL ONCOLOGY
, cilt.31, sa.27, ss.3439, 2013 (SCI-Expanded, Scopus)
2013
2013125. Evaluation of Quality of Life in Turkish Patients with Head and Neck Cancer
Akkas E. A., YÜCEL B., KILIÇKAP S., ALTUNTAŞ E. E.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION
, cilt.14, sa.8, ss.4805-4809, 2013 (SCI-Expanded, Scopus)
2013
2013126. Lack of Relationships between FGF19 Staining Pattern, Lymph Node Metastasis and Locally Invasive Characteristics of the Tumor in Colorectal Cancers
UNAL H. U., Demiralay E., Tepeoglu M., Fidan C., KILIÇKAP S.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION
, cilt.14, sa.5, ss.3151-3154, 2013 (SCI-Expanded, Scopus)
2012
2012127. Long-term complications in Hodgkin's lymphoma survivors
KILIÇKAP S., BARIŞTA İ., Ulger S., ÇELİK İ., SELEK U., Gullu I., et al.
TUMORI
, cilt.98, sa.5, ss.601-606, 2012 (SCI-Expanded, Scopus)
2011
2011128. Gastric cancer after cadaveric liver transplantation in a patient with autoimmune hepatitis: A case report and review of the literature
ARSLAN Ç., KILIÇKAP S., YALÇIN Ş.
TURKISH JOURNAL OF GASTROENTEROLOGY
, cilt.22, sa.1, ss.73-76, 2011 (SCI-Expanded, Scopus, TRDizin)
2011
2011129. Isolated Bone Metastases in Early Stage Endometrial Adenocarcinoma: A Case Report and Review of the Literature
Kurt M., KILIÇKAP S., AKSOY S., ERMAN M., Gedikoglu G., Turker A.
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
, cilt.21, sa.1, ss.52-56, 2011 (SCI-Expanded, Scopus, TRDizin)
2011
2011130. The First Line Systemic Chemotherapy in Metastatic Gastric Carcinoma: A Comparison of Docetaxel, Cisplatin and Fluorouracil (DCF) Versus Cisplatin and Fluorouracil (CF); Versus Epirubicin, Cisplatin and Fluorouracil (ECF) Regimens in Clinical Setting
KILIÇKAP S., YALÇIN Ş., ATEŞ Ö., Tekuzman G.
HEPATO-GASTROENTEROLOGY
, cilt.58, sa.105, ss.208-212, 2011 (SCI-Expanded, Scopus)
2010
2010131. Socio-demographic parameters in screening for breast cancer: Lessons from a population-based women's Health Project held in a province in Turkey
HAYRAN K. M., Abali H., KILIÇKAP S., MENTEŞ T., Aksoy H., Kemik A., et al.
JOURNAL OF BUON
, cilt.15, sa.4, ss.726-731, 2010 (SCI-Expanded, Scopus)
2010
2010132. The Effect on Prognosis of Postoperative CA 19-9 Level in Patients With Pancreatic Cancer
KILIÇKAP S., ARSLAN Ç.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
, cilt.33, sa.3, ss.320, 2010 (SCI-Expanded, Scopus)
2010
2010133. Fitting the Pieces of the POEMS Syndrome Jigsaw Puzzle-Guillain-Barre Syndrome in a Patient with Refractory Ascites: Case Report
Shorbagi A., ÖNAL İ. K., Onal E. D., KILIÇKAP S., BARIŞTA İ., Kansu T., et al.
TURKIYE KLINIKLERI TIP BILIMLERI DERGISI
, cilt.30, sa.1, ss.352-355, 2010 (SCI-Expanded, Scopus)
2009
2009134. A case of recurrent metastatic hepatocellular cancer controlled with immunotherapy and antiviral therapy following resection
KILIÇKAP S., Kars A., HAMALOĞLU E., ŞİMŞEK H.
MEDICAL ONCOLOGY
, cilt.26, sa.4, ss.501-505, 2009 (SCI-Expanded, Scopus)
2009
2009135. Risk of Venous Thromboembolism With Bevacizumab in Cancer Patients
KILIÇKAP S., ARSLAN Ç.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
, cilt.301, sa.14, ss.1435, 2009 (SCI-Expanded, Scopus)
2008
2008136. Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin's lymphoma
KILIÇKAP S., Yavuz B., AKSOY S., Sahiner L., DİNÇER M., HARPUTLUOĞLU H., et al.
MEDICAL ONCOLOGY
, cilt.25, sa.4, ss.437-442, 2008 (SCI-Expanded, Scopus)
2008
2008137. Platelet size has diagnostic predictive value for bone marrow metastasis in patients with solid tumors
AKSOY S., KILIÇKAP S., Hayran M., HARPUTLUOĞLU H., KOCA E., Dede D. S., et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
, cilt.30, sa.3, ss.214-219, 2008 (SCI-Expanded, Scopus)
2008
2008138. A case report: zoledronic acid-induced anterior uveitis
KILIÇKAP S., Ozdamar Y., ALTUNDAĞ M. K., DİZDAR Ö.
MEDICAL ONCOLOGY
, cilt.25, sa.2, ss.238-240, 2008 (SCI-Expanded, Scopus)
2008
2008139. Characteristics of breast cancer patients with central nervous system metastases: A single-center experience
Harputluoglu H., DİZDAR Ö., AKSOY S., KILIÇKAP S., Dede D. S., Ozisik Y., et al.
JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION
, cilt.100, sa.5, ss.521-526, 2008 (SCI-Expanded, Scopus)
2008
2008140. Liver dysfunction after chemotherapy in lymphoma patients infected with hepatitis C
DİZDAR Ö., Tapan U., AKSOY S., Harputluoglu H., KILIÇKAP S., BARIŞTA İ.
EUROPEAN JOURNAL OF HAEMATOLOGY
, cilt.80, sa.5, ss.381-385, 2008 (SCI-Expanded, Scopus)
2008
2008141. Erectile dysfunction in successfully treated lymphoma patients
AKSOY S., HARPUTLUOĞLU H., KILIÇKAP S., DİNÇER M., DİZDAR Ö., AKDOĞAN B., et al.
SUPPORTIVE CARE IN CANCER
, cilt.16, sa.3, ss.291-297, 2008 (SCI-Expanded, Scopus)
2008
2008142. A decision-analytic model for early stage breast cancer: Lumpectomy vs mastectomy
Alogan G. B., Elele T., Hayran M., ERMAN M., KILIÇKAP S.
NEOPLASMA
, cilt.55, sa.3, ss.222-228, 2008 (SCI-Expanded, Scopus)
2007
2007143. The sign of Leser-Trelat
Kilickap S., Yalcin B.
NEW ENGLAND JOURNAL OF MEDICINE
, cilt.356, sa.21, ss.2184, 2007 (SCI-Expanded, Scopus)
2007
2007144. Early and late arrhythmogenic effects of doxorubicin
Kilickap S., Barista I., Akgul E., Aytemir K., Aksoy S., Tekuzman G.
SOUTHERN MEDICAL JOURNAL
, cilt.100, sa.3, ss.262-265, 2007 (SCI-Expanded, Scopus)
2007
2007145. A novel immunosuppressive agent, sirolimus, in the treatment of Kaposi's sarcoma in a renal transplant recipient
Yilmaz R., Akoglu H., Yirkpantur A., Kilickap S., Arici M., Altun B., et al.
RENAL FAILURE
, cilt.29, sa.1, ss.103-105, 2007 (SCI-Expanded, Scopus)
2007
2007146. Rituximab-related viral infections in lymphoma patients
Aksoy S., Harputluoglu H., Kilickap S., Dede D. S., Dizdar O., Altundag K., et al.
LEUKEMIA & LYMPHOMA
, cilt.48, sa.7, ss.1307-1312, 2007 (SCI-Expanded, Scopus)
2006
2006147. Extensive exfoliative dermatitis induced by chlorambucil
Kilickap S., Kurt M., Aksoy S., Erman M., Turker A.
AMERICAN JOURNAL OF HEMATOLOGY
, cilt.81, sa.11, ss.891-892, 2006 (SCI-Expanded, Scopus)
2006
2006148. Cutaneous metastases of signet cell carcinoma of the rectum without accompanying visceral involvement
Kilickap S., Aksoy S., Dincer M., Saglam E. A., Yalcin S.
SOUTHERN MEDICAL JOURNAL
, cilt.99, sa.10, ss.1137-1139, 2006 (SCI-Expanded, Scopus)
2006
2006149. Gefitinib efficacy in relapsed small-cell lung cancer
DİNÇER M., Aksoy S., Kilickap S., Altundag K.
LUNG CANCER
, cilt.53, sa.2, ss.255, 2006 (SCI-Expanded, Scopus)
2006
2006150. Accelerated hepatitis C virus replication with rituximab treatment in a non-Hodgkin's lymphoma patient
Aksoy S., Abali H., Kilickap S., Erman M., Kars A.
CLINICAL AND LABORATORY HAEMATOLOGY
, cilt.28, sa.3, ss.211-214, 2006 (SCI-Expanded, Scopus)
2006
2006151. Nasopharynx carcinoma complicated with pneumocephalus
Dizdar O., Kilickap S., Aksoy S., Cizginer S., Erman M.
JOURNAL OF NEURO-ONCOLOGY
, cilt.77, sa.1, ss.107-108, 2006 (SCI-Expanded, Scopus)
2006
2006152. Lithium-associated hypothyroidism and thyroid papillary carcinoma: A case report
Aksoy S., Kilickap S., Erman M.
SOUTHERN MEDICAL JOURNAL
, cilt.99, sa.3, ss.279-281, 2006 (SCI-Expanded, Scopus)
2006
2006153. Metastatic granular cell tumor: A case report and review of the literature
Aksoy S., Abali H., Kilickap S., HARPUTLUOĞLU H., Erman M.
ACTA ONCOLOGICA
, cilt.45, sa.1, ss.91-94, 2006 (SCI-Expanded, Scopus)
2006
2006154. Nonconvulsive status epilepticus due to ifosfamide
Kilickap S., ÇAKAR M., Onal I., Tufan A., Akoglu H., Aksoy S., et al.
ANNALS OF PHARMACOTHERAPY
, cilt.40, sa.2, ss.332-335, 2006 (SCI-Expanded, Scopus)
2006
2006155. Acrocyanosis as a presenting symptom of Hodgkin lymphoma
Solak Y., Aksoy S., Kilickap S., Celik I.
AMERICAN JOURNAL OF HEMATOLOGY
, cilt.81, sa.2, ss.151-152, 2006 (SCI-Expanded, Scopus)
2006
2006156. Treatment of comorbidities besides the treatment of primary tumor may further increase effective management of cancer
Aksoy S., Aksoy H., HARPUTLUOĞLU H., Kilickap S., Altundag K.
MEDICAL HYPOTHESES
, cilt.67, sa.4, ss.744-746, 2006 (SCI-Expanded, Scopus)
2005
2005157. Multivariate analysis of factors predictive of brain metastases in localised non-small call lung carcinoma
Kilickap S., Aksoy S., Erman M.
LUNG CANCER
, cilt.49, sa.1, ss.129, 2005 (SCI-Expanded, Scopus)
2005
2005158. Successful salvage therapy of resistant gestational trophoblastic disease with ifosfamide and paclitaxel
SHORBAGİ A., Aksoy S., Kilickap S., GÜLER N.
GYNECOLOGIC ONCOLOGY
, cilt.97, sa.2, ss.722-723, 2005 (SCI-Expanded, Scopus)
2005
2005159. Doxorubicin-induced second degree and complete atrioventricular block
Kilickap S., AKGUL E., Aksoy S., Aytemir K., Barista I.
EUROPACE
, cilt.7, sa.3, ss.227-230, 2005 (SCI-Expanded, Scopus)
2005
2005160. Successful treatment of a chemoresistant tumor with temozolomide in an adult patient: report of a recurrent intracranial mesenchymal chondrosarcoma
Aksoy S., Abali H., Kilickap S., GÜLER N.
JOURNAL OF NEURO-ONCOLOGY
, cilt.71, sa.3, ss.333-334, 2005 (SCI-Expanded, Scopus)
2005
2005161. Fludarabine phosphate may be useful in the treatment of graft-versus-host disease
Aksoy S., Abali H., Kilickap S., DİNÇER M., Erman M.
MEDICAL HYPOTHESES
, cilt.64, sa.6, ss.1150-1152, 2005 (SCI-Expanded, Scopus)
2004
2004162. CA 19-9 measurement as a screening: Higher cost, lower survival
Kilickap S., Abali H., Aksoy S., Celik I.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
, cilt.19, sa.12, ss.1428, 2004 (SCI-Expanded, Scopus)
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler
2020
20201. Akciğer Kanserli Hastalarda Günlük Yaşam Aktiviteleri İle Ilişkili Parametrelerin Incelenmesi
ŞAHİN H., SAĞLAM M., VARDAR YAĞLI N., KILIÇ K., ÇALIK KÜTÜKCÜ E., İNAL İNCE D., et al.
Türk Toraks Derneği 23.Yıllık Kongresi Bildiri Kitabı, Türkiye, 15 - 18 Ekim 2020, ss.147, (Özet Bildiri)
2020
20202. Multi-dimensional evaluation of daily living activities in lung cancer
ŞAHİN H., SAĞLAM M., VARDAR YAĞLI N., KILIÇ K., ÇALIK KÜTÜKCÜ E., İNAL İNCE D., et al.
European Respiratory Society Virtual Congress, 7 - 09 Eylül 2020, cilt.56, ss.2931, (Özet Bildiri)
2020
20203. Evaluation of functional exercise capacity using two-field test in lung cancer patients
VARDAR YAĞLI N., KILIÇ K., SAĞLAM M., ÇALIK KÜTÜKCÜ E., İNAL İNCE D., KILIÇKAP S.
European Respiratory Society Virtual Congress, 7 - 09 Eylül 2020, cilt.56, ss.278, (Özet Bildiri)
2020
20204. Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experience
Tural D., Olmez O. F., Sumbul A. T., Artac M., Ozhan N., Akar E., et al.
Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), San-Francisco, Kostarika, 13 - 15 Şubat 2020, cilt.38, (Özet Bildiri)
2019
20195. outcomes of patients with resected pancreatic ductal adenocarcinoma
ceylan f., GÜVEN D. C., çakır y., Hamaloglu E., Karakoc D., TÜRKER F. A., et al.
9th international gastrointestinal cancer conference, 6 - 08 Aralık 2019, (Tam Metin Bildiri)
2019
20196. Gemcitabine Based Trimodality Treatment in Patients WithMuscle Invasive Bladder Cancer: Hacettepe University Experience
Esen Ç. S. B., HÜRMÜZ P., KILIÇKAP S., ÖZYİĞİT G., AKYOL H. F.
6th CONGRESS OF THEMEDITERRANEAN MULTIDISCIPLINARY ONCOLOGY FORUM3rd INTERNATIONAL CONGRESS ON ONCOLOGICAL SCIENCES, 27 Kasım - 01 Aralık 2019, cilt.5, (Tam Metin Bildiri)
2019
20197. Determinants of Respiratory Muscle Strength in Lung Cancer
Kilic K., VARDAR YAĞLI N., SAĞLAM M., ÇALIK KÜTÜKCÜ E., İNAL İNCE D., ARIKAN H., et al.
European-Respiratory-Society (ERS) International Congress, Madrid, İspanya, 28 Eylül - 02 Ekim 2019, cilt.54, (Özet Bildiri)
2019
20198. Kolon kanseri tedavisi sonrası oksijen tüketimi, solunum kas kuvveti ve enduransı, fiziksel fonksiyon ve yorgunluğun incelenmesi: olgu sunumu
SANVER M. F., VARDAR YAĞLI N., SAĞLAM M., ÇALIK KÜTÜKCÜ E., İNAL İNCE D., KILIÇKAP S.
7. Ulusal Fizyoterapi ve Rehabilitasyon Kongresi, Türkiye, 18 - 20 Nisan 2019, cilt.30, ss.155, (Özet Bildiri)
2019
20199. Tip 2 diyabetli bireylerin fiziksel aktivite düzeyleri ve sağlıklı yaşam biçimi davranışlarının incelenmesi
SANVER M. F., VARDAR YAĞLI N., SAĞLAM M., ÇALIK KÜTÜKCÜ E., İNAL İNCE D., KILIÇKAP S.
7. Ulusal Fizyoterapi ve Rehabilitasyon Kongresi, Türkiye, 18 - 20 Nisan 2019, cilt.30, ss.154-155, (Özet Bildiri)
2019
201910. IMMUNE-RELATED ADVERSE EVENTS INDUCED BY CANCER IMMUNOTHERAPIES. BIG DATA ANALYSIS OF 13,051 CASES (IMMUNOCANCER INTERNATIONAL REGISTRY)
Ramos-Casals M., Lambotte O., Kostine M., Calabrese L., Suarez-Almazor M., Bingham C., et al.
Annual European Congress of Rheumatology (EULAR), Madrid, İspanya, 12 - 15 Haziran 2019, cilt.78, ss.607-608, (Özet Bildiri)
2019
201911. Clinical features and prognosis of patients with liposarcoma: Single-center experience.
Demir M., Guven D. C., Aktas B. Y., Guner G., Aktepe O. H., Taban H., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2019, cilt.37, (Özet Bildiri)
2019
201912. Akciğer kanserinde yürüme sırasındaki işin solunum kas kuvveti ile ilişkisi
VARDAR YAĞLI N., KILIÇ K., SAĞLAM M., İNAL İNCE D., ÇALIK KÜTÜKCÜ E., KILIÇKAP S.
Türk Toraks Derneği 22.Yıllık Kongresi, Türkiye, 10 - 14 Nisan 2019, ss.490, (Özet Bildiri)
2018
201813. EFFECTS OF CANCER TYPES ON LOCAL AND OUT-OF-CITY ADMISSIONS FOR MEDICAL CARE
HAYRAN K. M., YÜCE D., KILIÇKAP S., DİZDAR Ö., houssein b., ERMAN M., et al.
ISPOR Asia Pacific 2018, Tokyo, Japonya, 8 - 11 Kasım 2018, (Özet Bildiri)
2018
201814. TRANSCULTURAL ADAPTATION OF EORTC-QLQ-CR29 SCALE INTO TURKISH, AND ASSESSMENT OF VALIDITY ANDRELIABILITY IN TURKISH PATIENTS WITH COLORECTAL CANCER
HAYRAN K. M., YÜCE D., KILIÇKAP S., houssein b., ERMAN M., DİZDAR Ö., et al.
ISPOR Asia Pacific 2018, Tokyo, Japonya, 8 - 11 Kasım 2018, cilt.1, ss.11, (Tam Metin Bildiri)
2018
201815. Metastatic Choroidal Melanoma: Single Center Experience
AKTAŞ B. Y., GÜNER G., DEMİR M., GÜVEN D. C., AKTEPE O. H., BÖLEK E. Ç., et al.
2. Ulusal İmmunoterapi ve Onkoloji Kongresi, Antalya, Türkiye, 31 Ekim - 04 Kasım 2018, ss.1-48, (Tam Metin Bildiri)
2018
201816. Do cancer treatments affect pain perception?
KILIÇ K., VARDAR YAĞLI N., SAĞLAM M., ÇALIK KÜTÜKCÜ E., İNAL İNCE D., ARIKAN H., et al.
28th European Respiratory Society Annual Congress, 15 - 19 Eylül 2018, cilt.52, ss.2468, (Özet Bildiri)
2018
201817. Respiratory muscle strength, respiratory muscle endurance, functional capacity and cognitive status in lung cancer patients
KILIÇ K., VARDAR YAĞLI N., SAĞLAM M., ÇALIK KÜTÜKCÜ E., İNAL İNCE D., ARIKAN H., et al.
28th European Respiratory Society Annual Congress, 15 - 19 Eylül 2018, cilt.52, ss.2477, (Özet Bildiri)
2018
201818. Analysis of Fusobacterium nucleatum, Streptococcus gallolyticus and Porphyromonas gingivalis in saliva in colorektal patients and healty controls. Abst ID:”e15117”
GÜVEN D. C., DİZDAR Ö., ALP A., Akdoğan Kittana F. N., KARAKOÇ D., Hamaloğlu E., et al.
2018 ASCO, Chicago, Amerika Birleşik Devletleri, 1 - 05 Haziran 2018, (Özet Bildiri)
2018
201819. Yüksek Dereceli Rekürren Glial Tümör Tanılı Hastada Bevacizumabın Olası Bir Yan Etkisi Olarak Multipl Arteriovenöz Malformasyon
ELMALI DOĞAN A., MUT AŞKUN M., YÜCE SARI S., KILIÇKAP S., ZORLU A. F., YAZICI G.
13.ULUSAL RADYASYON ONKOLOJİSİ KONGRESİ, Türkiye, 27 Nisan - 01 Mayıs 2018
2018
201820. Akciğer kanserli hastalarda kognitif durumun fonksiyonel kapasite ve fiziksel aktivite ile ilişkisi
KILIÇ K., VARDAR YAĞLI N., SAĞLAM M., ÇALIK KÜTÜKCÜ E., ARIKAN H., İNAL İNCE D., et al.
Türk Toraks Derneği 21.Yıllık Kongresi, Türkiye, 11 - 15 Nisan 2018, ss.326, (Özet Bildiri)
2018
201821. Akciğer kanserli bireylerde solunum kas enduransının değerlendirilmesi
KILIÇ K., VARDAR YAĞLI N., SAĞLAM M., ÇALIK KÜTÜKCÜ E., İNAL İNCE D., ARIKAN H., et al.
Türk Toraks Derneği 21.Yıllık Kongresi, Türkiye, 11 - 15 Nisan 2018, ss.324, (Özet Bildiri)
2017
201722. Akciğer kanserli bireylerde ağrı durumunun değerlendirmesi
KILIÇ K., VARDAR YAĞLI N., SAĞLAM M., ÇALIK KÜTÜKCÜ E., İNAL İNCE D., ARIKAN H., et al.
1. Kardiyopulmoner Rehabilitasyon Kongresi, Türkiye, 22 Mayıs - 25 Kasım 2017, cilt.29, (Özet Bildiri)
2017
201723. Akciğer kanserinde kognitif durumun incelenmesi
KILIÇ K., VARDAR YAĞLI N., SAĞLAM M., ÇALIK KÜTÜKCÜ E., İNAL İNCE D., ARIKAN H., et al.
1. Kardiyopulmoner Rehabilitasyon Kongresi, Türkiye, 22 - 25 Kasım 2017, cilt.29, (Özet Bildiri)
2018
201824. Kolorektal Kanserli Hastalarda Ve Sağlıklı Kontrollerde Tükürükte Fusobacterium Nucleatum, Streptococcus Gallolyticus Ve Porphyromonas Gingivalis Analizi
GÜVEN D. C., DİZDAR Ö., ALP A., AKDOĞAN KITTANA F. N., KARAKOÇ D., HAMALOĞLU E., et al.
7. Türk Tıbbi Onkoloji Kongresi, Antalya, Türkiye, 21 - 25 Mart 2018, (Özet Bildiri)
2017
201725. Brain Tissue Follow-up Using Dynamic Susceptibility Contrast-Enhanced and Dynamic Contrast-Enhanced Perfusion Magnetic Resonance Imaging on Lesions Categorized by Apparent Diffusion Coefficient Values in Glioblastoma
OMAY B., ARDALI S., MUT AŞKUN M., KILIÇKAP S., ERMAN M., KARLI OĞUZ H. K.
Radiology Society of North America, 26 Kasım - 01 Aralık 2017, (Özet Bildiri)
2017
201726. Erlotinib tedavisine direnç gösteren akciğer kanseri olgusu
BABAOĞLU E., KILIÇKAP S., SARINÇ ULAŞLI S., KÖKSAL D.
TÜSAD 2017, Türkiye, 14 - 17 Ekim 2017, (Özet Bildiri)
2017
201727. Opere evre 1A küçük hücreli dışı akciğer kanserli hastada erken nüks mü biyolojik yapıştırıcı reaksiyonu mu?
KÖKSAL D., BABAOĞLU E., KILIÇKAP S., SARINÇ ULAŞLI S., DOĞAN R.
TÜSAD 2017, Türkiye, 14 - 17 Ekim 2017, (Özet Bildiri)
2017
201728. Erlotinib tedavisine direnç gelişen akciğer adenokanseri olgusu
BABAOĞLU E., KILIÇKAP S., SARINÇ ULAŞLI S., KÖKSAL D.
TÜSAD 2017, Türkiye, 14 - 17 Ekim 2017, (Özet Bildiri)
2017
201729. Reinforcement of mental health in an interaction group of cancer patients
HAYRAN K. M., Kamışlı S., küçükçoban ş., ÇELİK İ., KILIÇKAP S., YÜCE D.
2017 World Congress of Psycho-Oncology, 14 - 18 Ağustos 2017, (Özet Bildiri)
2017
201730. Efficiency of a psychoeducational Intervention for smoking cessation in a specialized cessation clinic
YÜCE D., KAMIŞLI S., KÜÇÜKÇOBAN ş., HAYRAN K. M., KILIÇKAP S., ÇELİK İ., et al.
2017 World Congress of Psycho-Oncology, 14 - 18 Ağustos 2017, (Özet Bildiri)
2017
201731. Cancer patients and oncology nursing from the perspectives of oncology nurses in Turkey
Kamışlı S., YÜCE D., karakılıç B., KILIÇKAP S., HAYRAN K. M.
2017 World Congress of Psycho-Oncology, 14 - 18 Ağustos 2017, (Özet Bildiri)
2017
201732. Characteristics of Turkish colorectal cancer patients and bevacizumab preference.
Cicin I., Gumus M., Uncu D., Ozkan M., Kilickap S., Elkiran T. E., et al.
53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, Illinois, Amerika Birleşik Devletleri, 2 - 07 Haziran 2017, cilt.35, (Özet Bildiri)
2017
201733. Smoker relatives of inpatients: A reasonable but heterogeneous target population for smoking cessation program
AKTAŞ B. Y., HOUSSEİN b., YÜCE D., DİZDAR Ö., KILIÇKAP S., ERMAN M., et al.
7th ECTOH Conference on Tobacco or Health, Porto, Portekiz, 22 - 25 Mart 2017, (Özet Bildiri)
2016
201634. Tirozin Kinaz İnhibitörü Kaynaklı Tiroid Fonksiyon Bozukluğu
TECEN K., ÖZDEMİR N., KARA E., EKİNCİOĞLU A., DEMİRKAN S. K., ERMAN M., et al.
18. ULUSAL İÇ HASTALIKLARI KONGRESİ, Türkiye, 12 - 16 Ekim 2016, (Özet Bildiri)
2016
201635. Using geographical information systems to describe quality of life as a function of distance in cancer patients
HAYRAN K. M., ERMAN M., KILIÇKAP S., DİZDAR Ö., YÜCE D., HÜSEYİN B., et al.
ISPOR Asia Pacific Meeting 2016, 3 - 06 Eylül 2016, cilt.19, ss.892, (Özet Bildiri)
2016
201636. Plasma caveolin-1 level: A prognostic marker for pancreatic cancer.
Demirci N. S., Dogan M., Erdem G. U., Kacar S., Turhan T., Yilmaz F. M., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 3 - 07 Haziran 2016, cilt.34, (Özet Bildiri)
2015
201537. The clinical role of Ga-68 DOTATE PET-CT in patients with neuroendocrine tumors
TUNCEL M., KILIÇKAP S., Akdemir E.
28th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Hamburg, Almanya, 10 - 14 Ekim 2015, cilt.42, (Özet Bildiri)
2015
201538. Adaptation of an ensemble of complementary neural networks with adjusted average error to other prediction models
YILMAZ IŞIKHAN S., KARABULUT E., KILIÇKAP S.
International Society for Clinical Biostatistics 36th Annual Conference, Utrecht, Hollanda, 23 - 27 Ağustos 2015, (Özet Bildiri)
2015
201539. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer
Ateş Ö., Babacan T., SARICI F., KERTMEN N., CENOLİ A., Akın S., et al.
ASCO Annual Meeting, 29 Mayıs - 02 Haziran 2015, (Tam Metin Bildiri)
2015
201540. Turkish National Colon Cancer Registry.
Benekli M., Dumanli E., Kilickap S., Uncu D., Aliustaoglu M., Cicin I., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri)
2015
201541. Association of age with breast cancer clinical and pathological factors: Analysis of Turkish National Breast Cancer Registry.
Benekli M., Altundag K., Dumanli E., Isikdogan A., Karaoglu A., Tekin S. B., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri)
2015
201542. Factors that affect the suitability of cancer patients for clinical drug trials in Turkey: Final analysis of a multicenter study.
Erman M., Kilickap S., Ekinci A. S., Koca S., Ata A., Besen A., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri)
2015
201543. Turkish National Gastric Cancer Registry.
Buyukberber S., Dumanli E., Uncu D., Ozkan M., Uslu R., Dogu G. G., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri)
2015
201544. Association of obesity with breast cancer clinical and pathological factors: Analysis of Turkish National Breast Cancer Registry.
Coskun U., Altundag K., Aliustaoglu M., Uncu D., Ozkan M., Cicin I., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri)
2015
201545. Turkish National Breast Cancer Registry.
Altundag K., Dumanli E., Aliustaoglu M., Uncu D., Ozkan M., Cicin I., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri)
2015
201546. Geographic variations of clinical characteristics in breast cancer: Analysis of Turkish National Breast Cancer Registry.
Kilickap S., Altundag K., Dumanli E., Gumus M., Uslu R., Ozyilkan O., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri)
2015
201547. Clinical impact of Ga-68-DOTATATE in patients with neuroendrocrine tumors
TUNCEL M., KILIÇKAP S., Akdemir E.
3rd Theranostics World Congress on Gallium-68 and PRRT, Maryland, Amerika Birleşik Devletleri, 12 - 14 Mart 2015, cilt.56, (Özet Bildiri)
2014
201448. GENERIC IMATINIB MESYLATE IS AS EFFECTIVE AS ORIGINAL GLIVEC IN THE MANAGEMENT OF CML
AKSU S., AKTİMUR S., ARİCA D., ATAY M. H., BEKTAŞ Ö., BÜYÜKAŞIK Y., et al.
20th Congress of the European Hematology Association Vienna, Austria June 11-14,2015, 11 - 14 Haziran 2014, (Tam Metin Bildiri)
2014
201449. The diagnostic and prognostic value of UHRF-1 and p53 in gastric cancer.
Babacan N. A., Egilmez R., Yucel B., Seker M. M., Parlak I., Kacan T., et al.
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32, (Özet Bildiri)
2014
201450. Could the neutrophil to lymphocyte ratio be a poor prognostic factor for lung cancers?
Kacan T., Babacan N., Seker M. M., Yucel B., Behceci A., Gedikil M. A., et al.
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32, (Özet Bildiri)
2014
201451. İYİ DİFERANSİYE TİROİT KANSERLERİNDE TSH R METİLASYONUNUN ÖNEMİ
KARTAL K., KÖSEMEHMETOĞLU K., ÖNDER S. Ç., KILIÇKAP S., GÜLER TEZEL Y. G., KAYNAROĞLU Z. V.
19. Ulusal Cerrahi Kongresi, Türkiye, 16 - 20 Nisan 2014, (Özet Bildiri)
2014
201452. İyi Diferansiye Tiroit Kanserlerinde Tsh R Metilasyonunun Önemi
KARTAL K., KÖSEMEHMETOĞLU K., ÖNDER S. Ç., KILIÇKAP S., GÜLER TEZEL Y. G., KAYNAROĞLU Z. V.
19. Ulusal Cerrahi Kongresi, Türkiye, 16 - 20 Nisan 2014, (Özet Bildiri)
2014
201453. Temporal changes in the survival of metastatic renal cell cancer patients and the impact of targeted agents: Single center experience
Erman M., Arik Z., Kilickap S., Bilen C. Y., Yazici S., Akdogan B., et al.
Genitourinary Cancers Symposium, San-Francisco, Kostarika, 30 Ocak - 01 Şubat 2014, cilt.32, (Özet Bildiri)
2012
201254. Bevacizumab (BEV) plus capecitabine as maintenance therapy after initial treatment with BEV plus XELOX in previously untreated patients (pts) with metastatic colorectal cancer (mCRC): Mature data from STOP and GO, a phase III, randomized, multicenter study
Yalcin S., Uslu R., Dane F., Yilmaz U., Zengin N., Buyukunal E., et al.
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 - 06 Haziran 2012, cilt.30, (Özet Bildiri)
2006
200655. Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin's lymphoma
Kilickap S., Yavuz B., Aksoy S., Sahiner L., Harputluoglu H., Dincer M., et al.
30th Congress of the European-Society-for-Medical-Oncology, İstanbul, Türkiye, 29 Eylül - 03 Ekim 2006, cilt.17, ss.202, (Özet Bildiri)
Kitaplar
2019
20191. esophaeal and gastroesophaeal junction tumors
YALÇIN Ş., DİZDAR Ö., KILIÇKAP S., cilbir e., philip p. a.
textbook of gastrointestinal oncology, Suayib Yalcin, Philip a. Philip, Editör, springer, ss.55-72, 2019
Desteklenen Projeler
2017 - 2018
2017 - 2018
Triple Negatif Meme Kanseri Hücrelerinde Regorafenib uygulamasının Sisplatin tedavisine katkısı
Yükseköğretim Kurumları Destekli Proje , BAP Diğer
KILIÇKAP S. (Yürütücü), GÜRLER F.
2017 - 2017
2017 - 2017Amerikan Klinik Onkoloji Cemiyeti Yıllık Kongresi (ASCO2017)
Yükseköğretim Kurumları Destekli Proje , BAP Diğer
KILIÇKAP S. (Yürütücü), YÜCE D.
2015 - 2016
2015 - 2016Nöroendokrin tümörlü hastalarda Ga68 DOTATE PETBTnin klinik rolü
Yükseköğretim Kurumları Destekli Proje , BAP Diğer
TUNCEL M. (Yürütücü), KILIÇKAP S.
2015 - 2016
2015 - 2016
Etkileşim Gruplarında Kanser Hastalarının Başetmeleri
Yükseköğretim Kurumları Destekli Proje , BAP Diğer
HAYRAN K. M. (Yürütücü), KILIÇKAP S., KAMIŞLI S., YÜCE D., ÇELİK İ., KÜÇÜKÇOBAN Ş.
2015 - 2015
2015 - 2015Düzeltilmiş ortalama hatalı tamamlayıcı yapay sinir ağlarının bir bütünleyicisinin diğer kestirim modellerine adaptasyonu
Yükseköğretim Kurumları Destekli Proje , BAP Diğer
YILMAZ S. (Yürütücü), KARABULUT E., KILIÇKAP S.
2015 - 2015
2015 - 2015
Hacettepe Üniversitesi Kanser Enstitüsü ve M.D. Anderson Kanser Merkezi Uluslararası Onkoloji Sempozyumu
Yükseköğretim Kurumları Destekli Proje , BAP Diğer
HÜRMÜZ P. (Yürütücü), KILIÇKAP S., ÖZYİĞİT G.